Cargando…
Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). It was developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd for the cure of non-small cell lung cancer (NSCLC). In May 2016, OTB was approved in South...
Autores principales: | Attwa, Mohamed W., Kadi, Adnan A., Darwish, Hany W., Abdelhameed, Ali S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091481/ https://www.ncbi.nlm.nih.gov/pubmed/35558213 http://dx.doi.org/10.1039/c8ra08161a |
Ejemplares similares
-
Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability
por: Kadi, Adnan A., et al.
Publicado: (2016) -
A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes
por: Attwa, Mohamed W., et al.
Publicado: (2022) -
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability
por: Abdelhameed, Ali S., et al.
Publicado: (2019) -
LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways
por: Kadi, Adnan A., et al.
Publicado: (2018) -
A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2021)